Supernus Pharmaceuticals Obligated to Pay $33.4 Million in CVR Milestone Payment
Supernus Pharmaceuticals to make $33.4 million CVR milestone payment
Image: Investing Australia
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) is set to pay approximately $33.4 million to holders of its Contingent Value Rights (CVRs) after achieving a milestone on March 18, 2026. The payment of $0.50 per CVR will be distributed within 20 business days of the notice date, which was May 17, 2026.
- 01Supernus Pharmaceuticals has a market capitalization of $2.83 billion.
- 02The cash payment of $0.50 per CVR is subject to applicable withholding taxes.
- 03The company reported $207.7 million in total revenues for Q1 2026, surpassing the forecast of $192.96 million.
- 04Despite revenue growth, Supernus reported a GAAP net loss of $2.3 million, equating to a loss of $0.04 per diluted share.
- 05Supernus' stock is currently trading at $48.68, considered undervalued according to InvestingPro's analysis.
Advertisement
In-Article Ad
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) announced an obligation to pay approximately $33.4 million to holders of its Contingent Value Rights (CVRs) after achieving a milestone on March 18, 2026. This payment, amounting to $0.50 per CVR, is set to be distributed within 20 business days of the notice date, which was May 17, 2026. The company, which has a market capitalization of $2.83 billion, holds more cash than debt according to InvestingPro's analysis, indicating a strong financial position to meet this obligation. In its recent Q1 2026 earnings report, Supernus showcased a total revenue of $207.7 million, exceeding forecasts of $192.96 million. However, despite this revenue growth, the company reported a GAAP net loss of $2.3 million, translating to a loss of $0.04 per diluted share, falling short of the expected $0.1933. Currently trading at $48.68, Supernus is regarded as undervalued, presenting potential investment opportunities.
Advertisement
In-Article Ad
The milestone payment could positively affect investor confidence in Supernus Pharmaceuticals, potentially leading to increased stock value.
Advertisement
In-Article Ad
Reader Poll
Do you think Supernus Pharmaceuticals will continue to grow after this milestone?
Connecting to poll...
Read the original article
Visit the source for the complete story.